Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Bhopal: Bhopal Memorial Hospital & Research Center (BMHRC) will close two main offices.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
2.
RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung
3.
In a study, immune detection of oral cancers is linked to obesity.
4.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
5.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
1.
An Overview Of Serum Osmolality: What Is It And How Can It Help You?
2.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
3.
Tazemetostat: A Promising New Treatment for Cancer
4.
The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide
5.
Understanding Villous Adenoma: Causes, Symptoms, and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge